Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27850
Title: The Feasibility of Quality Assurance in the TOPGEAR International Phase III Clinical Trial of Neoadjuvant Chemoradiotherapy for Gastric Cancer (An Intergroup Trial of the AGITG/TROG/EORTC/CCTG).
Austin Authors: Lukovic, J;Moore, A J;Lee, M T;Willis, D;Ahmed, S;Akra, M;Hortobagyi, E;Lim Joon, Daryl ;Kron, T;Liu, Z;Ryan, J;Thomas, M;Wall, K;Ward, I;Wiltshire, K L;O'Callaghan, C J;Wong, R K;Ringash, J G;Haustermans, K;Leong, T 
Affiliation: Austin Health
Cancer Care Services, Sunshine Coast University Hospital, Birtinya, Australia
Peter MacCallum Cancer Centre, Melbourne, Australia
Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
Hunter New England Health, New South Wales, Australia
Liverpool and Macarthur Cancer Therapy Centre, Sydney, Australia
University of Newcastle, Newcastle, Australia
Division of Radiation Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada
Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada
Radiation Medicine Program, University Health Network and Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
Canterbury Regional Cancer and Haematology Service, Christchurch, New Zealand
Issue Date: 1-Nov-2021
Publication information: International Journal of Radiation Oncology, Biology, Physics 2021; 111(3S): S38-S39
Abstract: The TOPGEAR (Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma) international phase III trial hypothesized that adding preoperative chemoradiation (CRT) to perioperative chemotherapy will improve survival in patients (pts) with gastric cancer. Owing to the complexity of gastric irradiation, a comprehensive radiation therapy quality assurance (RTQA) program was implemented. The objective of this report is to describe the RTQA methods and outcomes. RTQA was undertaken in 'real time' prior to treatment for the first 5 pts randomized to CRT from each center. Once acceptable quality was achieved, RTQA was completed for one third of subsequent cases. RTQA consisted of evaluating the following parameters: 1) clinical target volume (CTV) and organ-at-risk (OAR) contouring; 2) RT planning parameters (CT simulation, dose prescription/planning technique, per-protocol planning constraints). Protocol violations between high- (defined as 20+ pts enrolled) and low-volume centers were compared using Fisher's exact test. As of December 2020, 554 pts from 70 centers were enrolled. In total, 277 were randomized to receive RT and 196 (71%) were included for RTQA; of these, 57 (29%) and 139 (71%) were from high- and low-volume centers, respectively. The initial RTQA pass rate was 72% (n = 141). There was no significant difference in the initial pass rate between the high- and low-volume centers (79% vs 69%; P = 0.22) For the 55 cases requiring resubmission, detailed feedback was provided, and most cases had multiple protocol violations. At least one aspect of the CTV had to be adjusted in 49/55 (89%) cases with inadequate coverage of the duodenum down to the 3rd part most commonly seen (n = 28/55, 51%). Table 1 summarizes CTV contouring protocol violations. OARs were generally appropriately contoured with five (9%) cases requiring adjustment. Two cases failed RTQA due to treatment planning violations (kidney dose, lung dose) in absence of contouring (CTV, OAR) concerns. Following resubmission, 192 (98%) passed RTQA and four (2%) required a second resubmission. In a large multicenter trial RTQA is feasible and effective in achieving high quality RT treatment plans. Ongoing education and audits should be performed to ensure consistent quality of treatment plans over the study period.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27850
DOI: 10.1016/j.ijrobp.2021.07.111
ORCID: 0000-0002-1947-9694
Journal: International Journal of Radiation Oncology, Biology, Physics
PubMed URL: 34700546
PubMed URL: https://www.redjournal.org/article/S0360-3016(21)00981-0/fulltext
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on Apr 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.